ISTH 2022 Supported Symposia & Presentation Theaters
(as of7/10/22)

​

The following companies will organize supported symposia and/or presentation theater sessions at the ISTH 2022 Congress in London, showcasing the latest scientific, diagnostic and therapeutic advances in thrombosis and hemostasis. 

​

See below for session titles.

​

Live Supported Symposia and Presentation Theaters

​​

Saturday, July 9, 11:30 – 12:45 Supported Symposia

• AAV Gene Therapies: Learnings From Clinical Trials to Inform Real World Discussions (BioMarin Pharmaceutical Inc.) ICC Capital Suites 7&12

• Anticoagulant Advancements for VTE in All Ages and NVAF in Adult Patients (Boehringer Ingelheim) ICC Capital Suites 10&11

• Living with ITP: Thrombotic Risk and Patient’s Perspective (GRIFOLS) ICC Capital Suite 1

• A Key Factor: Aiming for All-Round Bleed Protection in Haemophilia A (Octapharma AG) ICC Capital Suites 14-16

• Shining a Light on Severe Congenital Protein C Deficiency (SCPCD) (Takeda Pharmaceutical Company Limited) ICC Capital Suites 8&9

​

Sunday, July 10, 07:00 – 07:45 Supported Symposium

• Navigating the Joint Health Journey for Patients With Hemophilia: How Can You Make A Lasting Impact? (MedScape/ISTH/Takeda Pharmaceuticals U.S.A, Inc.) ICC Capital Suite 1

​

Sunday, July 10, 12:15 – 13:00 Presentation Theaters

• Achieving Balance with Prophylaxis in Hereditary Factor X Deficiency – Treatment Across the Ages (Bio Products Laboratory Ltd.) Presentation Theater 3

• MRX PT DOAC – a New Way to Measure the Effect of DOACs (Nordic Biomarker) Presentation Theater 4

• Rapid Reversal of DOACs: Current and Future Perspectives (Norgine) Presentation Theater 2

• Managing the Challenges of IVDR Transition Together (Siemens Healthineers) Presentation Theater 1

​

Sunday, July 10, 13:15 – 14:30 Supported Symposia

• Make the Right Call: Protecting Vulnerable Patients With Venous Thrombosis (Bayer AG) ICC Capital Suites 2-4

• Advancing Care for Haemophilia: How Do We Keep Up With the Times? (CSL Behring) ICC Capital Suites 7&12

• Evidence-Based Responses to Key Clinical Questions Relating to Hemophilia A Management (F. Hoffmann-La Roche Ltd) ICC Capital Suites 10&11

• COVID-19 Coagulopathy and Long COVID: Haemostatic Changes and Implications for Diagnosis and Treatment (Haemonetics Corporation) ICC Capital Suites 17

• Health Equity for Haemophilia Patients with Inhibitors: Can We Do More? (LFB) ICC Capital Suite 1

• Mind the Gap: The Journey to Address Unmet Needs Across all Haemophilia Indications (Novo Nordisk) ICC Capital Suites 14-16

• Immune Thrombocytopenia: Disease Burden and Treatment Challenges in the COVID-19 Era (Sanofi) ICC Capital Suites 8&9

​

Monday, July 11, 07:00 – 07:45 Supported Symposium

• Management of Thrombosis in High-Risk Patients: Focus on Cancer-Associated Thrombosis (CAT) (Anthos Therapeutics) ICC Capital Suite 17

​

Monday, July 11, 07:00 – 07:45 Presentation Theater

• Implementing a Multimodal Approach to VTE Prevention Today (Cardinal Health) ICC Capital Suite 1

​

Monday, July 11, 12:15 – 13:00 Presentation Theaters

• Advances in von Willebrand Disease (vWD): A View From the Clinic (CSL Behring) Presentation Theater 3

• Driving Change: Improving Diagnosis of Heavy Menstrual Bleeding and Bleeding Disorders in Women and Girls (Novo Nordisk Healthcare AG) Presentation Theater 4

• Lupus Anticoagulant Diagnostics: Why you Need More Snakes (Technoclone) Presentation Theater 1

• ADAMTS13 and von Willebrand Factor Axis (Werfen) Presentation Theater 2

​

Monday, July 11, 13:15 – 14:30 Supported Symposia

• Roundtable Discussion: Clinical Challenges in Patients with Venous Thromboembolism – Following the Data (BMS/Pfizer) ICC Capital Suites 14-16

• Improving Patient Care through Innovative Thrombosis and Haemostasis Testing. LumiraDx: Microfluidic Technology in POC Testing (LumiraDx) ICC Capital Suites 1

• Approaches to Standardisation and Monitoring for Haemophilia Gene Therapy: Consistency, Considerations and Challenges (Pfizer) ICC Capital Suites 7&12

• Improving Outcomes in Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Can We Reduce Mortality? (Sanofi) ICC Capital Suites 10&11

• Factors to Consider: Expert Perspectives on Haemophilia A (Sobi Sanofi) ICC Capital Suites 8&9

• A Chronic Disease Burden: Exploring the Acute and Long-term Manifestations of TTP on Patients’ Lives (Takeda Pharmaceutical Company Limited) ICC Capital Suites 2-4

 

Tuesday, July 12, 12:15 – 13:00 Presentation Theaters

• Breakthrough Applications for Thrombin Generation (Diagnostica Stago) Presentation Theater 4

• Current Advances in Deficient Factors, D-Dimer and Thrombophilia Testing (HORIBA Medical) Presentation Theater 3

• Insights From Real World Practice to Support Haemophilia B Patients (Sobi Sanofi) Presentation Theater 1

• Building a Future in Haemostasis: A new-age in Laboratory Workflow and Automation with the Sysmex CN-Series (Sysmex) Presentation Theater 2

​

Tuesday, July 12, 13:15 – 14:30 Supported Symposia

• Strategies for Assessing and Managing DOAC-Related Bleeding (AstraZeneca) ICC Capital Suites 10&11

• Focus on Females: Patient Experience & Novel Treatment Strategies in Bleeding Disorders (Octapharma AG) ICC Capital Suites 7&12

• Advances in Diagnosis and Management of Bleeding Disorders (Roche) ICC Capital Suites 2-4

• Medically-Ill Patients: VTE Prophylaxis in Hospital and Beyond (Sanofi) ICC Capital Suites 14-16

• Towards Health Equity: Upcoming Standards in Haemophilia Management (Sanofi) ICC Capital Suite 1

• Immune Thrombocytopenia: A Numbers Game? (Sobi) ICC Capital Suites 8&9

• Looking Towards the Future: Individualizing Treatment for Patients with Congenital and Acquired Hemophilia A (Takeda Pharmaceutical Company Limited) ICC Capital Suite 17

​

For more information on these sessions, visit the online program here.